NeuBase Therapeutics Inc

NASDAQ:NBSE   3:59:44 PM EDT
5.04
+0.40 (+8.62%)
Earnings Announcements

Neubase Therapeutics Estimates Cash And Cash Equivalents Are Sufficient To Fund Currently Planned Operating & Capex Into Q1 Of Cy2022

Published: 12/23/2020 21:25 GMT
NeuBase Therapeutics Inc (NBSE) - Neubase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020.
Neubase Therapeutics - Estimates Cash and Cash Equivalents Are Sufficient to Fund Currently Planned Operating & Capex Into Q1 of Cy2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.22

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.25

More details on our Analysts Page.